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ABSTRACT 
 
Objective: Evaluate benefit and risk of low dose growth hormone treatment (GHT, 4.5 
mg/m2/week) in very young children with Prader-Willi Syndrome (PWS).  
 
Design: Prospective longitudinal clinical intervention. 
 
Methods: We evaluated 31 infants (aged 2-12 months) and 42 toddlers  (13-24 months) from 
the PWS-OZGROW database for height, weight and BMI using the World Health Organization 
standard deviation scores (SDSWHO) and PWS specific BMI (SDSPWS), bone age, insulin-like growth 
factor 1 (IGF-I) levels and adverse events over 3 years of GHT. 
 
Results: At commencement of GHT infants had a lower BMI SDSWHO (-0.88 vs 0.40) than toddlers, 
while toddlers had a lower height SDSWHO (-1.44 vs -2.09) (both P<0.05). All increased height 
SDSWHO (2 year delta height infants +1.26 SDS, toddlers + 1.21 SDS), but infants normalised 
height sooner, achieving a height SDS of -0.56 within 1 year, while toddlers achieved a height 
SDS of -0.88 in two years. BMI SDSWHO increased, while BMI SDSPWS decreased (both P<0.0001) 
and remained negative. The GHT response did not differ with gestation (preterm 23%) or genetic 
subtype (deletion vs maternal uniparental disomy). Bone age advancement paralleled 
chronological age.  All children had low serum IGF-I at baseline which increased, but remained 
within the age-based reference range during GHT (for 81% in first year). Four children had spinal 
curvature at baseline; two improved, two progressed to a brace and two developed an abnormal 
curve over the observation period. Mild to severe central and/or obstructive sleep apnoea were 
observed in 40% of children prior to GHT initiation; 11% commenced GHT on positive airway 
pressure (PAP), oxygen or both. Eight children ceased GHT due to onset or worsening of sleep 
apnoea: 2 infants in the first few months and 6 children after 6-24 months. Seven resumed GHT 
usually after adjusting PAP but five had adenotonsillectomy. One child ceased GHT temporarily 
due to respiratory illness. No other adverse events were reported. Two children substantially 
improved their breathing shortly after GHT initiation. 
 
Conclusion: Initiation of GHT in infants with 4.5 mg/m2/week was beneficial and comparable in 
terms of auxological response to a dose of 7 mg/m2/week. Regular monitoring pre and post GH 
initiation assisted in early detection of adverse events. IGF-I levels increased with the lower dose 
but not excessively, which may lower potential long-term risks. 
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Introduction 
 
In 2009 growth hormone treatment (GHT) was endorsed in Australia under the government GH 
program to treat children with genetically confirmed Prader-Willi Syndrome (PWS) until 18 years 
of age to improve linear growth and body composition [1]. PWS is caused by a lack of expression 
of imprinted genes on the paternally derived chromosome 15q11-13 [2]. Complications at birth 
are frequent and assisted delivery is necessary in the majority of cases [3]. Approximately half of 
the infants with PWS are transferred to a special care unit due to various problems, e.g. 
hypoglycaemia, inability to suckle or breathing difficulties [4, 5]. In infancy the first signs of PWS 
are typically hypotonia, hypogonadism, failure to thrive and developmental delay [6]. 
Characteristic clinical features include short stature, which is exacerbated during childhood and 
adolescence, and abnormal body composition, i.e. high fat mass and low lean tissue mass, which 
is already present in infancy [7]. Due to an increase in appetite (hyperphagia), which follows the 
early feeding difficulties and is already present in up to 25% of children with PWS before their 
third birthday [8], the child may rapidly become obese if access to food is not restricted and 
physical activity not encouraged. Mild to moderate intellectual disability, and behavioural and 
psychological problems may become apparent in later childhood [6, 9]. 
 
Children with PWS improve height and body composition with GHT [6, 10] irrespective of 
whether treatment is based on genetic diagnosis or on anthropometric criteria as we previously 
reported [11]. In young children a positive effect on motor function and muscle strength/tone 
has been noted [10, 12]. Developmental milestones may be reached at an earlier age and mental 
development and adaptive skills may be improved [13, 14].  However, in most GH studies 
reported to date very few children were less than 1 year old when GHT was started and were 
grouped together in the analysis with toddlers [14, 15] or 3 to 4 year old children [16, 17]. 
Valuable information may have been lost as the young child goes through several nutritional 
phases from failure to thrive in infancy to a period of no difficulty in feeding and appropriate 
growth around 9 to 25 months before excessive weight gain becomes an ongoing health issue 
[8]. 
 
Despite the documented benefits of early initiation of GHT in PWS [6, 14, 16], there may be 
some hesitation to commence GHT in very young children because of the wide array of 
difficulties in infancy and the paucity of publications on the optimal dose and time to commence 
as well as safety, for example with respect to upper airway compromise secondary to lymphoid 
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hyperplasia in infants with PWS [18-20].  In addition, concern has been raised with respect to the 
long-term effect of elevated levels of insulin-like growth factor-1 (IGF-I) above the reference 
range with the usual recommended GH dose of 7 mg/m2/week or higher [20]. 
 
In this study we aimed to evaluate: 
 The auxological response of very young children treated with a GH dose of 4.5 mg/m2/week, 
which is a relatively low dose compared to the recommended standard (7 mg/m2/week) in 
PWS [20, 21]  
 Early initiation of GHT by comparing the response of infants (aged ≤ 12 months) and toddlers 
(aged 13-24 months), which closely resemble the nutritional phases of the “failure to thrive 
stage” and the “normal feeding and growth period” respectively [8]  
 IGF-I response of both age groups to the relatively low dose of GHT 
 Occurrence of adverse events, such as respiratory compromise and scoliosis. 
We also report on bone age (BA), waist circumference, hypotonia, developmental delay, spinal 
curvature and occurrence of sleep disordered breathing over the first two years. 
The recently recommended World Health Organisation (WHO) and PWS specific standards were 
used to analyse height, weight and body mass index (BMI) standard deviation scores (SDS).  
 
Subjects and methods 
 
Data from all young children (≤ 24 months) with genetically confirmed PWS who commenced 
GHT were selected from the Australian PWS-OZGROW database [11], which combines de-
identified patient data from the OZGROW database containing the anthropometric data of all 
children on the government GH program with additional information and data obtained from 
private patients pre 2009. All children were GH naïve. Ethics approval was obtained from the 
participating hospitals and universities. Parental consent to participate in OZGROW and the PWS 
database was obtained separately by the treating physicians.  
 
Data were collected from birth or six months prior to commencement of GHT during standard 
consults of the child with their endocrinologist.  These data are a requirement for the provision 
of government-sponsored GH and included gender, birth weight and length, gestation, genetic 
diagnosis (subtype optional), age, height, weight, BA (Greulich and Pyle) and since 2009, IGF-I, 
waist circumference, sleep study evaluation and observations on hypotonia, developmental 
delay and spinal curvature. Follow up data and GH dose were reported quarterly in the initial 
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period, then bi-annually except BA, which was assessed annually. Clinical measurements were 
obtained by the hospital growth/endocrine clinic nurse using calibrated scales for weight, a 
Harpenden stadiometer for standing height and supine height/length of children <2 years of age. 
Waist circumference was measured midway between the lower costal border of 10th rib and 
iliac crest. The IGF-I measurements were evaluated with the age-related reference range for 
each laboratory where they had been performed (95% confidence interval, CI) and classified 
according to where they fell in relation to the reference range as follows: Low (below), Normal 
(within age-based reference range: N- lower and N+ upper half) or High (above reference range). 
Data on hypotonia and developmental delay were based on the clinical assessment of the 
treating endocrinologist experienced in PWS, during the child’s normal consult. In the absence of 
a practical validated tool these were scored as absent, mild, moderate or severe. Data on spinal 
curvature (scoliosis and kyphosis) were assessed by the specialist using x-ray results when 
applicable and scored as absent (Cobb angle ≤ 10 o, mild (10o < angle < 20o), moderate (20o < 
angle < 55o) or severe (angle ≥ 55o). The ratio of BA over chronological age (BA/CA) is presented 
after 2 years of GHT due to the high error range in infancy. Sleep studies, overnight 
polysomnography (PSG) (see reference [22] for details), were performed before and within 6 
months after starting GHT as a requirement of the GH program. The PSG reports on sleep state, 
arousals and respiratory events, e.g. apnoea/hypopnoea. Reports on sleep disordered breathing 
(SDB) may include obstructive apnoea (OSA), apnoea of central origin (CSA) or mixed events and 
snoring with advice on treatment (e.g. CPAP (for OSA), supplemental oxygen (for CSA) or referral 
for tonsillectomy). Adverse events were also mandatory to report. 
 
The GH dose in PWS commences at 4.5 mg/m2/week in Australia (Genotropin, Pfizer Australia, 
Sydney). The dose may be increased with increments of 1.5 mg/m2/week at 6 monthly intervals 
to a maximum of 7.5 mg/m2/week if any one of the response criteria is not met [1]. The 
response criteria include growth (e.g. improving height centile/BMI SDS (CDC), waist 
circumference SDS and/or waist/height ratio) and body composition, but not IGF-I level, 
although downward dose adjustments are allowed. The visit date at which GH was approved or 
started by the specialist was used to obtain the baseline measurements. The mean GH dose was 
calculated from baseline. 
 
Age and gender specific SDS for height (length if age < 2 years, referred to as height throughout), 
weight and BMI were calculated for each child using the WHO standards [23]. These include the 
age appropriate parameters for infants up to 60 months and have been recommended by the 
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Centers for Disease Control (CDC) and the Australian government for children up to 24 months 
[24]. For continuity, the WHO standards were used in the analysis of the first few years of GHT, 
and unless otherwise specified, any discussion of SDS refers to the WHO standard — indicated as 
SDSWHO. We also calculated the BMI SDS with the PWS specific standards (SDSPWS) by Hauffa [25] 
and with the CDC 2000 (BMI SDSCDC)[26].  
 
Data were analysed with SPSS version 22. Normality was checked with the Shapiro-Wilk and 
Kolmogorov Smirnov tests. Results are reported as mean and standard deviation (SD) unless 
otherwise stated. Continuous data, eg height, weight and BMI SDS, were analysed with 
Generalised Linear Modelling (GLM) univariate (two-way Analysis of Variance) to assess for 
significance, covariates and interaction between variables of interest and a GLM repeated 
measures was used to assess the significance of the mean change of continuous data over time.  
A t-test was used to compare the means of continuous data between infants and toddlers at 
particular year levels and a paired t-test to compare the WHO and CDC results of the same 
individuals. Boxplots and medians were used when normality was not achieved. For non-
parametric data, comparisons of proportions were tested with the 𝜒2 test.  
 
Results 
 
Seventy nine children with genetically confirmed PWS, who started GHT within the first 2 years 
of life (≤ 24 months), were selected from the PWS-OZGROW database. Six had insufficient long 
term GH data but are included in the evaluation of adverse events. Seventy three (51% males 
and 49% females), had at least two years of GH treatment and were analysed in depth with 
multifactorial design. Sixty children completed 3 years of GHT and some up to 7 years. Thirty one 
(42%) of the 73 started GHT as infants — age ≤12 months (mean ± SD; 8.3±2.5 months) and 42 
(58%) as toddlers — age 13 to 24 months (18.1±3.6 months) (Table 1). The gestation period 
ranged from 30 to 41 weeks. Six infants and 11 toddlers (total 23%) were born preterm 
(gestation < 37 weeks).  The proportion of babies born preterm did not differ between the 
infants and toddlers (𝜒2c, P=0.69, Table 1) and were included in all analyses. Birth length and 
birth weight did not differ between the infant and toddler group or for gender – GLM univariate, 
all P>0.05 (Table 1). Birth length of males vs females overall was 48.6±3.6 vs 48.9±2.9 cm; birth 
weight 2.53±0.65 vs 2.63±0.52 kg respectively. 
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Prior to 2009 commencement of GHT was either on a private script (8 infants, 1 toddler) or 
government-funded under the general criteria (1) based on their height (1 infant, 10 toddlers). 
Since 2009 all children started GHT under the PWS indication of the GH program and were 
managed according to a standardised protocol of dosing and data collection specific for PWS. 
There was no significant difference in mean height SDSWHO at baseline whether GH was started 
pre or post 2009 for the two age groups (GLM univariate, n=73, P=0.31). 
 
Height, weight, BMI, waist circumference and BA 
 
Gender and gestation were not significantly associated with height, weight or BMI SDSWHO at 
baseline (all P>0.05), but the age at which GHT was started was significantly associated with all 
three (GLM univariate, n=73, starting age (as covariate) PHeight=0.012, PWeight=0.030 and 
PBMI<0.0001 respectively), substantiating further analysis by age groups.  
 
At baseline the mean BMI SDSWHO of infants was below zero and significantly lower than that of 
toddlers (-0.88 ±1.43 vs 0.40±1.36, P=0.0002) while toddlers had a lower height SDSWHO (-
1.44±1.26 vs -2.09 ±1.29 SDSWHO, P=0.034) (Table 2). The difference in height and BMI SDS 
between infants and toddlers persisted in the first two years of GHT (GLM repeated measures; 
n=73, Ptime trend<0.0001, height SDSWHO, Page groups=0.009; BMI SDSWHO, Page groups=0.004). Figure 1A, 
1B present the height and BMI SDSWHO of all individuals who completed 2 years (n=73) and 3 
years (n=60) of GHT.  
 
Infants increased height and BMI SDSWHO to within -0.6 SDSWHO from zero in the first year with a 
significant mean change (± standard error) in height SDSWHO (0.88±0.15 SE) and BMI SDSWHO 
(1.16±0.22 SE) (both PY1 vs Y0 <0.0001, pairwise comparisons of the above mentioned analysis) 
with a further mean increase only in height SDSWHO of 0.38±0.11 SE (PY2 vs Y1=0.006) in the 2
nd 
year.  Toddlers, however, were very small (short) at baseline and increased height to within -1 
SDSWHO from zero over 2 years of treatment with a significant mean change in both years of 
0.96±0.13 SE (PY1 vs Y0<0.0001) and 0.25±0.09 SE (PY2 vs Y1=0.02) respectively. The BMI SDSWHO of 
toddlers was in the normal range at baseline and in the first year, but significantly increased in 
the second year with a mean change 0.68±0.20 SE (PY2 vs Y1=0.004). 
 
The BMI with WHO standards are high compared to the traditional CDC standards (Year 2, BMI 
SDSWHO vs SDSCDC, Paired t-test, P<0.0001; see Table 2). After two years of GHT 19% (4 infants, 10 
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toddlers) had become overweight (>2 BMI SDSWHO). Two children were ceased after three and 
four years respectively because of continuously increasing obesity (BMI >>2 SDS, i.e. >200% ideal 
body weight for height). 
 
The PWS specific BMI SDSPWS at baseline was positive (P<0.001) for both groups and did not 
differ between infants and toddlers (Table 2). After two years of GHT the BMI SDSPWS had fallen 
significantly to a negative range (GLM repeated measures, Ptime trend<0.0001, Page groups=0.31). The 
mean change in the first year was -0.53±0.09 (PY1 vs Y0<0.0001) and in the second -0.27±0.08 (PY2 vs 
Y1=0.004). Figure 1C presents the data including the third year. The BMI SDSPWS remained 
negative over the following years when individuals who had completed additional years of GHT 
were included (Year 2 to Year 7) and is presented in boxplots due to extreme values (Figure 2). 
 
The mean waist/height ratio did not differ between the age groups and significantly decreased in 
the first year only (GLM repeated measures, n=44, Ptime trend<0.001, Page groups=0.94, with a mean 
change of -0.5±0.1 SE, PY1 vs Y0=0.001) (Table 2).  
 
Bone age advancement paralleled chronological age (Table 2). It was not reported in the first 
year of GHT due to the high error range of BA in younger children. The mean BA/CA ratio after 
two (n=73) and three years (n=53) of GHT was 0.80±0.15 and 0.82±0.17 for infants and 
0.68±0.16 and 0.75±0.17 for toddlers respectively. The mean change in infants (n=26) and 
toddlers (n=27) was not significant (P>0.05, Paired sample t-test). 
 
Prematurity  
 
Gestational age by gender and chronological age at baseline as covariate was not significantly 
associated with either height, weight or BMI SDSWHO (GLM, PHeight=0.10, PWeight=0.14 or 
PBMI=0.51). However, there was an interaction with age groups at baseline of children born 
preterm vs term in height SDSWHO (GLM univariate, prematurity, P=0.11, interaction P=0.003), 
such that children born preterm were very small if they started GHT as an infant, but not if 
started as a toddler (Preterm vs Term; Infants, -2.7±1.1 vs -1.1 ±1.1; Toddlers, -1.7 ±1.5 vs -
2.2±1.2 SDSWHO). Nevertheless, 2 of the 5 smallest infants were born at term as were 4 of the 5 
infants with the lowest BMI SDSWHO.  The youngest infant (32 weeks gestation) started GHT at 8 
weeks and had no adverse events reported.  
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Genetic subtype 
 
All children were genetically confirmed as a requirement to obtain GH via the PWS indication. 
Further testing for subtype was recommended but optional. The genetic subtype was known for 
61 children: 48% had a deletion, 51% maternal uniparental disomy (UPD) and 2% imprinting 
disorder (Table 1). Children with a deletion or UPD did not significantly differ in mean height, 
weight and BMI SDSWHO at baseline (GLM, genetic subtype with age at start of GHT as covariate, 
PHeight=0.051, PWeight=0.55, PBMI=0.44). Although genetic subtype did not differ significantly 
between infants and toddlers in terms of height at baseline (PHeight =0.10), toddlers with UPD 
(n=17) showed a non-significant trend to be shorter (Del vs UPD; Infants, n=25, -1.5±1.3 vs -
1.5±1.3, Toddlers, n=35, -1.4±1.4 vs -2.5±1.0 SDSWHO, PInteraction =0.08).  
 
GH dose and IGF-I 
 
The mean GH dose did not significantly differ between infants and toddlers (Table 2) or from 4.5 
mg/m2/week after one or two treatment years (t-test PY1=0.59, PY2=0.14). The range was 3.11 to 
6.79 mg/m2/week. The mean GH dose was slightly higher in the second and third treatment year 
(paired t-test, mean difference Y2-1, 0.11±0.20, n=73, P<0.001; Y3-2, 0.08±0.19, n=60, P=0.001). 
 
The IGF-I at baseline was below the age specific reference range in 68% of infants (n=28) and in 
80% of toddlers (n=35) (Table 2). All other values were in the lower half of the normal reference 
range, which included 0 for infants when measured in U/mL. After initiation of GHT the majority 
of IGF-I values (infants 69%, toddlers 86%) were within the normal age based reference range 
and did not differ between infants and toddlers (𝜒2c =0.08, Table 2), with only 19% in total above 
the reference range. After two years of GHT 37% (Table 2) and after 3 years 36% (n=28) of all 
values were above the reference range. The very low IGF-I values reported after starting GHT 
were usually associated with gaps in GH supply, e.g. when adenotonsillectomy was 
recommended. 
 
Hypotonia, developmental delay, spinal curvature 
 
All children (27 infants, 34 toddlers), who were evaluated since 2009, were hypotonic and 
developmentally delayed at baseline, most only mildly so (mild: moderate: severe hypotonia, 
Infants 63%: 22%: 15% vs Toddlers 56%: 29%: 15%, 𝜒2=0.81; and mild: moderate: severe 
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developmental delay, Infants 74%: 26%: 0% vs Toddlers 68%: 29%: 3%, 𝜒2c = 0.79, moderate & 
severe combined). After one year GHT most were found to be mildly hypotonic (92%) and mildly 
developmentally delayed (93%) with 15% and 7% of the infants moderately hypotonic and 
developmentally delayed respectively. After two years of GHT (n=54) 6% remained moderately 
hypotonic and 9% moderately developmentally delayed. 
 
Three children had scoliosis (2 mild, 1 moderate) and one had mild kyphosis at baseline. All four 
were moderately developmentally delayed, one with severe, one with moderate and two with 
mild hypotonia. The scoliosis of the two children with moderate and severe hypotonia 
progressed and they were subsequently treated with a brace. The other two with initially mild 
spinal curvature improved, also in tone and developmental delay. After 2 years GHT 2 infants 
had developed a mild abnormal curve.  
 
Respiratory events 
 
Forty percent (13 infants, 16 toddlers) of the 72 children with sleep study results had sleep 
disordered breathing (SDB) with either mild to severe obstructive apnoea (OSA) and/or central 
sleep apnoea (CSA) or snoring at baseline, but sleep studies were not done or reported 
consistently prior to 2009.  
 
Twenty eight percent (20 children) had either had tonsillectomy and/or respiratory support prior 
to GHT: 7% (5 children) had adenotonsillectomy for mild to moderate OSA prior to starting GHT, 
3% (2 children) used a steroid nasal spray which they continued to use after commencement of 
GHT and 18% (7 infants, 6 toddlers) were treated with positive airway pressure (PAP), oxygen or 
both prior to commencement of GHT. Seven percent ceased respiratory support prior to 
commencing GHT (3 children ceased oxygen and 2 ceased CPAP). One infant ceased CPAP but 
continued on oxygen while six other children also continued using respiratory support. One child 
ceased CPAP shortly after commencing GHT. A further child was documented to be receiving 
supplemental oxygen after one year due to persistent oxygen requirement but had no baseline 
report. Clinical intervention for sleep disordered breathing was under supervision of a sleep 
physician. 
 
Most children (60%) needed no intervention prior to commencing GHT and had either 
uneventful sleep studies or mild central SDB or OSA on follow up studies. Breathing improved 
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substantially in two (3%) and remained relatively stable after initiation of GHT in the majority of 
children with at least 1 year GHT.  
 
Eight children (11%) ceased GHT due to an increase in OSA in the first 24 months of GHT. Four of 
these had uneventful sleep studies and four had mild or controlled central SDB and/or OSA prior 
to commencing GHT. Two (3%) were infants who developed severe OSA in the first few months. 
One resumed GHT after adenotonsillectomy and with positive airway pressure, the other has not 
recommenced despite being stabilized after a year. All others ceased after 6 to 24 months of 
GHT and recommenced within 3 to 12 months. Five had adenotonsillectomy, but one toddler, 
who had reasonable control of hypoventilation and on supplemental oxygen prior to GHT, 
needed several adjustments to the equipment and a repeat adenoidectomy. One child ceased 
GHT temporarily after 21 months due to recurrent respiratory illness. No other adverse events 
were reported. 
 
Discussion 
 
Initiation of GHT at a dose of 4.5 mg/m2/week in very young children with PWS (≤ 2 years of age) 
increased linear growth and IGF-I and was associated with few adverse events in the initial 
treatment period (addressing priority 3 of the GH Research Society workshop [20]. There was a 
concomitant decrease in PWS specific BMI SDS which may have been facilitated by either direct 
or indirect effects of GHT through improved mobility and physical activity and hence increased 
energy expenditure [12, 13], or through improvements in current dietary advice, stimulation of 
activity and early intervention in general.  
 
Gender, genetic subtype or period of gestation (23% was born preterm) were not associated 
with height or BMI SDSWHO at baseline, but age at which GHT started (as a covariate) was 
significantly associated with height SDSWHO and BMI SDSWHO substantiating separate analysis of 
infants (aged ≤ 12 months) and toddlers (13-24 months) in line with their nutritional phases as 
suggested by Miller et al [8].  
 
Infants normalised height to within -0.6 SDSWHO of the mean within the first year. Toddlers 
improved height to within -1 SDS after two years GHT which was a similar response as the 
overall Australian paediatric cohort based on diagnosis in our previous report [11]. The mean 
change in height during the first year of GH treatment was just under 1 SDS in both groups 
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(Infants, 0.88 SDSWHO, Toddlers 0.96 SDSWHO). Given the baseline values of infants were closer to 
zero than those of the older group, infants normalised their height SDS earlier then the toddlers.  
 
The lower BMI SDSWHO of infants (-0.9±1.4) at baseline is not surprising in PWS, given the initial 
phase of failure to thrive typical for infants. The toddler group (0.4±1.4 BMI SDSWHO) was already 
in the second nutritional phase of no difficulty in feeding [8]. Hence to avoid bias towards 
normality, data of infants should not be grouped together with older children under age three. 
Both groups increased BMI SDSWHO, but while an increase in BMI SDS of infants is encouraged, in 
toddlers this may be a sign of incipient obesity. Weight gain may initially be overlooked as it 
usually starts before the increase in appetite appears (nutritional phase 2a between 2.1-4.5 
years of age) [8] . Emphasis on dietary advice and management is especially important at this 
stage to prevent rapid escalation of weight as parents may overestimate the nutritional need of 
their toddler.  Indeed some gained weight rapidly resulting in a BMI of well over 2 SDS and a lack 
of restricting access to food seems likely.  
 
The PWS specific BMI SDS did not differ between infants and toddlers as may be expected. 
Improvements in current neonatal nutritional intervention may explain the slightly positive value 
at baseline of both age groups (approximately 0.5 SDSPWS) and updated PWS specific growth 
charts as currently available are valuable for future use in children up to 3 years of age [27]. 
Importantly, the PWS specific BMI SDS had decreased significantly after two years of GHT into a 
negative range.  Increased motor development and physical activity at an earlier age may have 
contributed to the reduction in the BMI SDSPWS [28]. The reduction in the median PWS specific 
BMI was consistent over 7 years and in a similar range of -0.5 to -1 SDSPWS as reported in an 8 
year study using a  higher GH dose of 7 mg/m2/day [29], suggesting a reduction in the risk of 
obesity in early childhood in PWS at either dose. Nevertheless, early diagnosis and non- growth 
hormone interventions, particularly dietetic, may have contributed to the observed 
improvement in BMI SDSPWS. 
 
The WHO standards which are recommended by the CDC for young children up to 2 years [24] 
tend to result in higher BMI SDS than when the CDC 2000 standards are used. The WHO 
standards are based on healthy, breastfed infants and compared with the reference data of the 
CDC 2000 fewer infants are classed as underweight [30]. The implication is important for infants 
with PWS who usually fail to thrive in the first year. Thus fewer infants with PWS appear 
underweight as would have been expected when using the CDC 2000 whereas older children 
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were sooner classed as overweight or obese once weight increased. The PWS specific reference 
standards reflect more appropriately the historical development of untreated children with PWS 
who evolve obesity with age. We therefore considered the PWS reference standards more 
useful to evaluate changes in the BMI SDS of children with PWS. 
 
Low IGF-I values are common in PWS [31] and most infants (68%) and toddlers (80%) had an IGF-
I at baseline that was below the age-based reference range. After initiation of GHT most children 
(81%) had IGF-I values within the normal range at a dose of 4.5 mg/m2/week. Increases in dose 
were few or minor as most children responded well with increased linear growth.  IGF-I values 
above the reference range increased in the cohort from 19% to 37% and 36% after 1, 2 and 3 
years of GHT respectively. This percentage is still of some concern as elevated IGF-I levels may 
contribute to lymphoid hyperplasia and associated OSA in young children after commencing GHT 
[32]. However, the percentage of children with elevated IGF-I levels was considerably less when 
compared to other studies using a higher dose of 7 mg/m2/week, in which the majority of 
children had an IGF-I level over 2 SDS after 2 or more years of treatment [29, 33] despite a 
similar linear growth response.  
 
Bakker et al [34] reported that the bioactivity of IGF-I was high in children (age ≤ 10 years) with 
high IGF-I SDS but less so in older children on GHT, necessitating downward adjustments in GH 
dose of young children with IGF-I>3 SDS. Thus the lower dose of 4.5 mg/m2/week may lower the 
long term risk associated with high IGF-I values in very young children, while sustaining 
improved height SDS. If height gain is monitored and not compromised, a downward titration of 
GH dose may be suggested in young children with high IGF-I values. 
 
The recommended starting dose in Australia (4.5 mg/m2/week) is substantially lower than those 
used in other studies [12, 13] or presently recommended elsewhere [20], but substantially 
higher than the dose of 2.1 mg/m2/week, which was considered ineffective in the only dose 
comparison study in PWS to date [21]. In this context it is noteworthy that surface area based 
dosing (using m2) as opposed to weight based dosing (using kg) results in relatively higher 
growth hormone doses in infants and younger children than older children [35]. Whether the 
dose used in Australia is sufficient to also substantially improve the lean to fat mass ratio in the 
long term is currently under investigation in our cohort as is the thyroid function and respiratory 
function. 
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A strength of our study is the standardised protocol for dosing, monitoring and data collection 
that applied to all patients treated with government-funded GH.  For example, a sleep study 
before and after initiation of GHT is mandatory. Mild to severe central and/or obstructive sleep 
apnoea were revealed in the pre-baseline sleep study in 40% of our cohort of young children, 
comparable to a report by Cohen et al of 43% central vs 35% obstructive sleep apnoea in 
children under two years of age [36]. Any serious respiratory problems revealed had to be 
addressed before growth hormone treatment could be initiated, e.g. five children (7%) had 
adenotonsillectomy pre GHT. Consequently, few infants had significant respiratory problems at 
commencement of GHT and if they did, such problems were manageable either with a steroid 
nasal spray (3%) or with positive airway pressure, supplemental oxygen or both (11% of initially 
18% continued this at commencement). Sleep evaluation of most children remained stable on 
follow up visits, while two (3%) improved substantially. However, two infants with no or mild 
respiratory issues developed severe OSA in the first few months of GHT, highlighting the 
importance of follow up sleep studies. Thirteen percent of children including the two above 
ceased GHT during the first 2 years of GHT, eight due to OSA and one due to recurrent 
respiratory illness. Eight of these recommenced within a year. While predominantly younger 
children had central SDB, many older children develop OSA with age [22, 36] and this may 
exclude them from GHT if the condition does not stabilize following treatment. An early start of 
GHT may thus be beneficial when monitored closely, while long term evaluation of our cohort 
may reveal whether a dose of 4.5 mg/m2/week GHT improves respiratory function and reduces 
the occurrence of adenotonsillar hypertrophy in PWS in the early primary school years. 
 
Four children had spinal curvature on commencement of GH treatment and only a few 
developed an abnormal curve during the second year of GHT. As the natural history is of 
increasing frequency and severity of spinal curvature with age, we may have started children on 
GH before spinal curvature had become evident. Although the effect of GHT on the natural 
development of spinal curvature is unclear, a large survey suggested that early introduction of 
GHT may delay or protect against progression of spinal curvature and reduce the risk for 
corrective surgery [37]. 
 
All infants and toddlers were hypotonic and developmentally delayed at baseline with no 
difference in the proportions between infants and toddlers. Most were only mildly hypotonic 
(59%) and mildly developmentally delayed (70%). Nearly all improved to the milder condition 
within the first year of GHT. Children may also show improvements in muscle tone and 
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developmental delay over time and hence this study could not determine the relative 
contribution of GHT. The improvement was especially noticeable in the more severely hypotonic 
children, which was consistent with other studies reporting that those with initially lower motor 
development improved the most with GHT [12, 13]. This is important as muscle strength in PWS 
is correlated with motor performance and muscle weakness is a limiting factor for motor 
development [38]. 
 
The limitations of this clinical cohort study relate mainly to the lack of reporting with regard to 
specific developmental milestones, such as independent standing and walking, and the scoring 
of hypotonia and developmental delay without a validated tool in the very young infants. 
Abnormal spinal curvature in infants with moderate to severe hypotonia can be difficult to 
assess. A method to objectively measure muscle strength has recently been developed [38] and 
its use in PWS will assist in a more detailed evaluation.  Another limitation was that any previous 
interventions, e.g. post-natal respiratory interventions or infections, were not consistently 
reported. Evaluation of any respiratory disorders and treatment were usually only provided 
within 6 months of baseline and during follow up.  
 
We conclude that treating infants whether born at term or preterm with low dose GH (4.5 
mg/m2/week) normalises IGF-I and height SDS within the first year with the risk of adverse side 
effects minimized if treatment is started after addressing any respiratory problems and closely 
monitored. Bone age did not accelerate. Overall, the earlier GHT was started the smaller the 
deficit in height SDS and the sooner this was normalised.  Improvements in height SDS and PWS 
specific BMI SDS appear comparable to reports using a higher dose of 7 mg/m2/week. Since the 
majority of IGF-I values remained within the age based reference range during our study this 
lower dose may reduce potential risks of long term treatment of very young children with PWS 
while retaining benefits in growth. 
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Figure 1 
Mean and 95% confidence interval of height and BMI SDS of 31 infants (black circles and bar) 
and 42 toddlers (light green square and bar) with Prader-Willi syndrome at baseline and after 1, 
2 and 3 years of GH treatment (Y3, n=60). (1A) height SDS (WHO) and (1B) BMI SDS (WHO) using 
WHO reference standards [23], and (1C) BMI SDS (PWS) using PWS specific reference standards 
by Hauffa [25].  
 
 
Figure 2 
Box plots of PWS specific BMI SDSPWS (median and interquartile range) of all young children 
combined at baseline (Y0) and subsequent years of GH treatment using the PWS specific 
reference standards by Hauffa [25]. Total number within parentheses. Circles are outliers 
(extreme values). 
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Table 1 
Birth characteristics of 73 infants and toddlers with Prader-Willi Syndrome. Del=Deletion, UPD= 
Maternal Uniparental Disomy, Imprint=Imprinting defect, P= Probability. 
 
 Infants Toddlers Infants vs 
Toddlers 
 Age ≤12 months 13 ≤ Age ≤24 months P t-test or 𝜒2c 
Total number 31 42  
Males: Females in % 55 : 45 48 : 52 0.71 
Birth; Preterm <37 weeks: Term in % 19 : 81 26 : 74 0.69 
Genetic subtype;    
Del: UPD: Imprint: not reported in % 36: 45: 3: 16 43: 40: 0: 17 0.76
a
 
Gestation (weeks); mean (SD) 37.8 (2.8) 38.3 (2.6) 0.42 
Birth length (cm); mean (SD) 48.6 (3.6) 48.8 (3.1) 0.80
b
 
Birth weight (kg); mean (SD) 2.59 (0.73) 2.57 (0.46) 0.93
c
 
a
 n=60, Deletion vs UPD only, 
 b
 n=57, 
c
 n=72 
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Table 2 
Mean (standard deviation) of 31 infants (aged ≤12 months) and 42 toddlers (13≤ age ≤24) with 
Prader-Willi syndrome at commencement (baseline), after one and after two years of growth 
hormone (GH) treatment. IGF-I = Insulin growth factor 1, L= Low (below) N= normal (N- lower 
half, N+ upper half), and H= High (above) recommended age-based reference range (95% 
confidence interval); P= Probability Infants vs Toddlers; SDSWHO, Standard Deviation Scores using 
WHO standards [23]; SDSPWS, using PWS specific standards by Hauffa [24]; SDSCDC using CDC 2000 
[25]; (n)= Total number 
 Infants  Toddlers  Infants vs Toddlers 
  Mean (SD)  Mean (SD)  P t-test or χ
2
c 
 (n=31)   (n=42)  
At initiation of GH treatment    
Age in months 8.3 (2.5) 18.1 (3.6)  
Height SDSWHO -1.44 (1.26) -2.09 (1.29) 0.034 
Weight SDSWHO -1.49 (1.30) -0.99 (1.31) 0.11 
BMI SDSWHO -0.88 (1.43) 0.40 (1.36) 0.0002 
BMI SDSPWS 0.58 (0.80) 0.51 (0.78) 0.68 
Waist/height in cm  (n) 0.63 (0.05)  (21) 0.62 (0.08)  (29) 0.35 
IGF-I, % L : N
- 
: N
+
 : H  (n) 68: 32 : 0 : 0  (28) 80 : 20 : 0 : 0  (35) 0.38
a
   
After 1 year GH treatment    
GH dose (mg/m
2
/week) 4.45 (0.44) 4.49 (0.48) 0.70 
Height SDSWHO -0.56 (0.97) -1.13 (1.19) 0.031 
Weight SDSWHO -0.15 (0.85) -0.30 (1.12) 0.54 
BMI SDSWHO 0.27 (1.01) 0.60 (1.14) 0.22 
BMI SDSPWS 0.20 (0.54) -0.14 (0.65) 0.021 
Waist/height in cm (n) 0.58 (0.04)  (22) 0.58 (0.06)  (31) 0.63 
IGF-I, % L : N
-
 : N
+
 : H (n) 3 : 41 : 28 : 28  (29) 3 : 52 : 35 : 10  (29) 0.18
b
 
After 2 years GH treatment    
GH dose (mg/m
2
/week) 4.51 (0.46) 4.64 (0.50) 0.27 
Height SDSWHO -0.18 (0.78) -0.88 (1.04) 0.002 
Weight SDSWHO 0.30 (0.96) 0.32 (1.45) 0.97 
BMI SDSWHO 0.57 (1.35) 1.27 (1.78) 0.07 
BMI SDSCDC 0.16 (1.39) 0.95 (1.68) 0.035 
BMI SDSPWS -0.25 (0.74) -0.28 (0.99) 0.83 
Bone age/chronological age 0.80 (0.15) 0.68 (0.16) 0.002 
Waist/height in cm (n) 0.55 (0.07)  (28) 0.57 (0.08)  (28) 0.43 
IGF-I, % L : N
-
 : N
+
 : H (n) 4 : 33 : 25 : 38  (24) 0 : 20 : 44 : 36  (25) 1.00
b 
a
= 𝜒2c Low vs normal;      
b
= 𝜒2c (Low + Normal) vs H;  
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Highlights 
 
In a cohort of infants and young children with PWS treated with Growth Hormone 
 A GH dose of 4.5 mg/m2/week may have equivalent effect as 7 mg/m2/week on height 
trajectory in young children 
 Infants normalised height with a GH dose of 4.5 mg/m2/week sooner than toddlers 
 PWS specific BMI SDS reduced to between -0.5 and -1 SDS after 2 years of GHT  
 IGF-I values increased but most remained within the age-based reference range 
 Mandatory sleep studies detected mild to severe central and/or obstructive apnoea in 40% 
of young children prior to GHT initiation.  
ACCEPTED MANUSCRIPT
